Literature DB >> 22507751

Increasing age at disability milestones among MS patients in the MSBase Registry.

Ilya Kister1, Eric Chamot, Gary Cutter, Tamar E Bacon, Vilija G Jokubaitis, Stella E Hughes, Orla M Gray, Maria Trojano, Guillermo Izquierdo, Francois Grand'Maison, Pierre Duquette, Alessandra Lugaresi, Pierre Grammond, Cavit Boz, Raymond Hupperts, Thor Petersen, Giorgio Giuliani, Celia Oreja-Guevara, Gerardo Iuliano, Jeannette Lechner-Scott, Roberto Bergamaschi, Maria Edite Rio, Freek Verheul, Marcela Fiol, Vincent Van Pesch, Mark Slee, Helmut Butzkueven, Joseph Herbert.   

Abstract

OBJECTIVE: To analyze time-trends in age at disability milestones among MS patients who were enrolled into the MSBase International Registry during 1996-2010 period.
METHODS: We used linear regression to describe the relationship between mean age at major EDSS benchmarks and calendar time. We then assessed time-trend in age at initial EDSS rating with a three level linear growth model specifying that patients were nested within each of 20 participating countries. The model estimated the average of time-trends in mean age at initial clinical assessment within each country while controlling for patients' EDSS and sex in each country. Analyses were repeated in subsamples of patients diagnosed according to Poser or McDonald criteria.
RESULTS: The MSBase Registry contained data on 11,108 MS patients enrolled between 1996 and 2010 who fulfilled our inclusion criteria. During the 1996-2010 period, enrollment age for patients with EDSS 4/4.5 increased by 7.9 years, from 43 to 51 years (p<0.001), and for EDSS 6/6.5 - by 4.9 years, from 48 to 53 year (p<0.001). These trends were consistent across 20 investigator countries and were observed in Poser-diagnosed as well as McDonald-diagnosed patient subsets.
CONCLUSIONS: The more recent MSBase enrollees in each of the mild-to-moderate disability strata were significantly older than earlier enrollees. Possible explanations for this phenomenon are discussed.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22507751     DOI: 10.1016/j.jns.2012.03.017

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  16 in total

1.  Natural history of multiple sclerosis symptoms.

Authors:  Ilya Kister; Tamar E Bacon; Eric Chamot; Amber R Salter; Gary R Cutter; Jennifer T Kalina; Joseph Herbert
Journal:  Int J MS Care       Date:  2013

2.  Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades: A Nationwide Population-Based Cohort Study in Sweden.

Authors:  Omid Beiki; Paolo Frumento; Matteo Bottai; Ali Manouchehrinia; Jan Hillert
Journal:  JAMA Neurol       Date:  2019-06-01       Impact factor: 18.302

3.  Late-onset MS is associated with an increased rate of reaching disability milestones.

Authors:  Mads Albrecht Andersen; Mathias Due Buron; Melinda Magyari
Journal:  J Neurol       Date:  2021-03-07       Impact factor: 4.849

4.  The outcome spectrum of multiple sclerosis: disability, mortality, and a cluster of predictors from onset.

Authors:  Helen Tedeholm; Bengt Skoog; Vera Lisovskaja; Björn Runmarker; Olle Nerman; Oluf Andersen
Journal:  J Neurol       Date:  2015-02-26       Impact factor: 4.849

5.  Disability in multiple sclerosis: a reference for patients and clinicians.

Authors:  Ilya Kister; Eric Chamot; Amber R Salter; Gary R Cutter; Tamar E Bacon; Joseph Herbert
Journal:  Neurology       Date:  2013-02-20       Impact factor: 9.910

6.  Technology-enabled assessments to enhance multiple sclerosis clinical care and research.

Authors:  Gabrielle Macaron; Brandon P Moss; Hong Li; Laura E Baldassari; Stephen M Rao; David Schindler; Jay L Alberts; Malory Weber; Malissa Ayers; François Bethoux; Adrienne Boissy; Desiree Chizmadia; Devon S Conway; Charlene Fink; Robert J Fox; Shauna Gales; Bethany Green; Claire Hara-Cleaver; Neal Jordan; Kedar R Mahajan; Marisa P McGinley; Deborah M Miller; Marie Namey; Alexander Rae-Grant; Mary Rensel; Hilary Young; Mary A Willis; Daniel Ontaneda; Jeffrey A Cohen; Robert A Bermel
Journal:  Neurol Clin Pract       Date:  2020-06

Review 7.  Apparent changes in the epidemiology and severity of multiple sclerosis.

Authors:  Nils Koch-Henriksen; Melinda Magyari
Journal:  Nat Rev Neurol       Date:  2021-09-28       Impact factor: 42.937

8.  Risk-benefit considerations in the treatment of relapsing-remitting multiple sclerosis.

Authors:  Alessandra Lugaresi; Maria di Ioia; Daniela Travaglini; Erika Pietrolongo; Eugenio Pucci; Marco Onofrj
Journal:  Neuropsychiatr Dis Treat       Date:  2013-06-24       Impact factor: 2.570

9.  Pediatric Multiple Sclerosis Severity Score in a large US cohort.

Authors:  Jonathan D Santoro; Michael Waltz; Greg Aaen; Anita Belman; Leslie Benson; Mark Gorman; Manu S Goyal; Jennifer S Graves; Yolanda Harris; Lauren Krupp; Timothy Lotze; Soe Mar; Manikum Moodley; Jayne Ness; Mary Rensel; Moses Rodriguez; Teri Schreiner; Jan-Mendelt Tillema; Emmanuelle Waubant; Bianca Weinstock-Guttman; Brigitte F Hurtubise; Shelly Roalstad; John Rose; T Charles Casper; Tanuja Chitnis
Journal:  Neurology       Date:  2020-07-20       Impact factor: 9.910

10.  Time to secondary progression in patients with multiple sclerosis who were treated with first generation immunomodulating drugs.

Authors:  H Tedeholm; J Lycke; B Skoog; V Lisovskaja; J Hillert; C Dahle; J Fagius; S Fredrikson; A-M Landtblom; C Malmeström; C Martin; F Piehl; B Runmarker; L Stawiarz; M Vrethem; O Nerman; O Andersen
Journal:  Mult Scler       Date:  2012-11-01       Impact factor: 6.312

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.